AlloHeme test accurately predicts relapse post-allo-HSCT in AML and MDS, with a median lead time of 36 days. The ACROBAT study involved 287 patients, showing significant predictive value of ...

TScan Therapeutics is developing TSC-101 and multiplex TCR-Ts for cancer treatment. See why TCRX stock holds potential with ...

FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) as ...

Copyright: © 2025 Published by Elsevier Ltd. The provision of a good paediatric haematopoietic stem-cell transplantation (HSCT) service requires significant skill ...

Besides their role in thrombosis and hemostasis, platelets can also stimulate fibrosis and tumor development by secreting profibrogenic factors and regulating the innate immune response, e.g., by ...

Methods: Diagnoses of HS were confirmed using immunohistochemistry, with markers such as CD68 and lysozyme. Treatment primarily involved anthracycline-based chemotherapy with autologous hematopoietic ...

Thrombocytopenia, which is a low platelet count, can be caused by problems in the bone marrow or the immune system. The bone marrow may not make enough platelets, or the immune system may destroy ...

Later that night, PLT posted, “We at Portsmouth Little Theatre would like to thank the community for the outpouring of concern for our injured actor. Our patrons have been so thoughtful and ...

Our objective is to build an accurate and fair survival prediction model for patients undergoing Hematopoietic Stem Cell Transplantation (HSCT).